Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar

AKMAN-DEMİR, Gülşen; KÜRTÜNCÜ, Murat; ALTUNRENDE, Burcu

doi:10.5505/epilepsi.2015.15807

Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar

Murat KÜRTÜNCÜ, (İstanbul Üniversitesi)

Burcu ALTUNRENDE, (İstanbul Bilim Üniversitesi)

Gülşen AKMAN-DEMİR (İstanbul Bilim Üniversitesi)

Epilepsi

27 0

Yıl: 2016 Cilt: 22 Sayı: Suppl. 1 Sayfa Aralığı: 53 - 66 Metin Dili: Türkçe DOI: 10.5505/epilepsi.2015.15807 İndeks Tarihi: 10-01-2020

Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar

Öz:

Sistemik otoimmün hastalıkların seyrinde merkezi sinir sistemi (MSS) nadir olmayarak tutulmaktadır. Bu hastalıklar içinde sistemik lupuseritematozus (SLE), romatoid artrit, Behçet hastalığı gibi bağ dokusu hastalıkları, sarkoidoz, granülomatöz anjit gibi granülomatöz hastalıklar,inflamatuvar bağırsak hastalıkları, Çölyak hastalığı gibi otoimmün bağırsak hastalıkları, Hashimoto ve Graves hastalığı gibi tiroid hastalıkları vardır. Bu hastalıkların seyrinde MSS tutulumuna bağlı lezyonlara sekonder epileptik nöbetler izlenebileceği gibi SLE gibi hastalıklardabelirgin bir lezyon olmadan da epilepsi ortaya çıkabilmektedir. Bu derlemede sistemik otoimmün hastalıklarda izlenen nörolojik tutulum,epileptik olaylar temel alınarak özetlenmektedir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp Romatoloji

Autoimmune Diseases Associated with Epilepsy

Öz:

Involvement of the central nervous system (CNS) during the course of systemic autoimmune diseases is not rare. Connective tissue disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, Behçet’s disease; granulomatous disorders such as sarcoidosis, granulomatous angitis; autoimmune bowel disorders such as inflammatory bowel and Celiac diseases; thyroid disorders such as Hashimoto and Graves diseases are best examples of the autoimmune diseases in this category. Epileptic seizures may be observed in patients with and without any obvious lesions in these disorders. In this review, we will summarize patterns of neurological involvement in systemic autoimmune diseases associated with epilepsy.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp Romatoloji

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42(4):599–608.
Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003;30(5):985–92.
Xuan Z, Yi D, Fu-Lin T, Fen-Chun Z. Central nervous system involvement in systemic lupus erythematosus in a hospitalbased study of 171 cases: the possible therapeutic role of intrathecal therapy. J Clin Rheumatol 1999;5(6):314–9.
Aszalós Z. Neurological and psychiatric manifestations of systemic lupus erythematosus and antiphospholipid syndrome. [Article in Hungarian] Orv Hetil 2011;152(15):597–605. [Abstract]
Kang EH, Shen GQ, Morris R, Metzger A, Lee EY, Lee YJ, et al. Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases. Lupus 2008;17(1):21–5.
Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006;33:1553–8.
Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006;54(8):2515–22.
Kozora E, West SG, Maier SF, Filley CM, Arciniegas DB, Brown M, et al. Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. J Neurol Sci 2010;295(1-2):87–91.
Levite M, Ganor Y. Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis. Expert Rev Neurother 2008;8(7):1141–60.
Levite M. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease gluta- mate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/ cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J Neural Transm (Vienna) 2014;121(8):1029–75.
Ndhlovu M, Preuss BE, Dengjel J, Stevanovic S, Weiner SM, Klein R. Identification of α-tubulin as an autoantigen recognized by sera from patients with neuropsychiatric systemic lupus erythematosus. Brain Behav Immun 2011;25(2):279–85.
Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99(4):397–401.
Formiga F, Moga I, Canet R, Pac M, Mitjavila F, Pujol R. Antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. [Article in Spanish] Rev Clin Esp 1996;196(11):734–6. [Abstract]
Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37(4):568–71.
Pan M, Tang HD, Zhu HQ, Dong J, Gill J, Zheng J. Partial epilepsy as an initial manifestation in bullous systemic lupus erythematosus. Lupus 2011;20(8):886–90.
Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004;63(10):1808–12.
Andrade RM, Alarcón GS, González LA, Fernández M, Apte M, Vilá LM, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008;67(6):829–34.
Honczarenko K, Budzianowska A, Ostanek L. Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome. Neurol Neurochir Pol 2008;42(6):513–7.
Butler S, Malone RJ. Seizure as a presenting symptom in neuropsychiatric systemic lupus erythematosus. Am J Phys Med Rehabil 2010;89(4):349.
Tsai JD, Lin CL, Lin CC, Sung FC, Lue KH. Risk of epilepsy in patients with systemic lupus erythematosus - a retrospective cohort study. Neuropsychiatr Dis Treat 2014;10:1635–43.
Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis 2012;71(9):1502–9.
Vieira-Karuta SC, Silva IC, Liberalesso PB, Bandeira M, Janz L Jr, Löhr A Jr. Epileptic seizures and EEG features in juvenile systemic lupus erythematosus. Arq Neuropsiquiatr 2008;66(3A):468– 70.
González-Duarte A, Cantú-Brito CG, Ruano-Calderón L, GarcíaRamos G. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol 2008;59(6):320–3.
Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005;64(12):2102–7.
Toyota T, Akamatsu N, Tanaka A, Shouzaki T, Tsuji S, Saito K, et al. Mesial temporal lobe epilepsy as a neuropsychiatric syndrome of systemic lupus erythematosus. Epilepsia 2013;54(3):33–6.
Lampropoulos CE, Koutroumanidis M, Reynolds PP, Manidakis I, Hughes GR, D’Cruz DP. Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum 2005;52(3):841–6.
Crespel A, Velizarova R, Agullo M, Gélisse P. Ethosuximideinduced de novo systemic lupus erythematosus with antidouble-strand DNA antibodies: a case report with definite evidence. Epilepsia 2009;50(8):2003.
Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol 2004;22(2):157–66.
Verma SP, Yunis N, Lekos A, Crausman RS. Carbamazepineinduced systemic lupus erythematosus presenting as cardiac tamponade. Chest 2000;117(2):597–8.
Mutoh K, Hidaka Y, Hirose Y, Kimura M. Possible induction of systemic lupus erythematosus by zonisamide. Pediatr Neurol 2001;25(4):340–3.
Kilfoyle DH, Anderson NE, Wallis WE, Nicholls DW. Recurrent severe aseptic meningitis after exposure to lamotrigine in a patient with systemic lupus erythematosus. Epilepsia 2005;46(2):327–8.
Gigli GL, Scalise A, Pauri F, Silvestri G, Diomedi M, Placidi F, et al. Valproate-induced systemic lupus erythematosus in a patient with partial trisomy of chromosome 9 and epilepsy. Epilepsia 1996;37(6):587–8.
Krämer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22(13):3411–20.
Sleegers MJ, Beutler JJ, Hardon WJ, Berden JH, Verhave JC, Conemans JM, et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J Am Geriatr Soc 2010;58(4):799–801.
Weide R, Heymanns J, Pandorf A, Köppler H. Successful longterm treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003;12(10):779–82.
Benavente E, Paira S, Roverano S, Saredo G. Encephalitis and status epilepticus in a patient with systemic lupus erythematosus. Reumatol Clin 2013;9(2):123–7.
Tsuji M, Tanaka H, Yamakawa M, Sagawa R, Azuma H. A case of systemic lupus erythematosus with complex partial status epilepticus. Epileptic Disord 2005;7(3):249–51.
De Maeseneire Ch, Duray MC, Rutgers MP, Gille M. Neurological presentations of the antiphospholipid syndrome: three illustrative cases. Acta Neurol Belg 2014;114(2):117–23.
Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74(6):1011–8.
Taipa R, Santos E. Primary antiphospholipid antibody syndrome presenting with encephalopathy, psychosis and seizures. Lupus 2011;20(13):1433–5.
Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010;40(4):350–9.
Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010;40(2):97–108.
Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999;8(2):127–33.
Sun KH, Liu WT, Tsai CY, Liao TS, Lin WM, Yu CL. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis 1992;51(6):707–12.
Riccio A, Andreassi C, Eboli ML. Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-Daspartate receptors. Neurosci Lett 1998;257(2):116–8.
Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol 2005;12(3):175–80.
Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci 1994;54(15):1119–25.
Cervera R, Boffa MC, Khamashta MA, Hughes GR. The EuroPhospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009;18(10):889–93.
Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci 2005;1051:465–86.
Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004;31(7):1344–8.
Seijo-Martínez M, Mosquera-Martínez JA, Romero-Yuste S, Cruz-Martinez J. Ischemic stroke and epilepsy in a patient with Tourette’s syndrome: association with the antiphospholipid syndrome and good response to levetiracetam. Open Neurol J 2008;2:32–4.
Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295(9):1050–7.
Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 2010;9(5):A305–10.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61(6):554–8.
Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjögren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 2000;123(1):46–57.
Bhattacharyya S, Helfgott SM2. Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis. Semin Neurol 2014;34(4):425–36.
Alexander EL, Ranzenbach MR, Kumar AJ, Kozachuk WE, Rosenbaum AE, Patronas N, et al. Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren’s syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994;44(5):899–908.
Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83(5):280–91.
Moreira I, Teixeira F, Martins Silva A, Vasconcelos C, Farinha F, Santos E. Frequent involvement of central nervous system in primary Sjögren syndrome. Rheumatol Int 2015;35(2):289–94.
Dong Y, Yang JL, Zhang NZ. The manifestations of the nervous system in primary Sjogren syndrome. [Article in Chinese] Zhonghua Nei Ke Za Zhi 1992;30(10):619-21, 658. [Abstract]
Yoshimura S, Nakamura H, Horai Y, Nakajima H, Shiraishi H, Hayashi T, et al. Abnormal distribution of AQP5 in labial salivary glands is associated with poor saliva secretion in patients with Sjögren’s syndrome including neuromyelitis optica complicated patients. Mod Rheumatol 2015:1–21.
Teixeira F, Moreira I, Silva AM, Vasconcelos C, Farinha F, Santos E. Neurological involvement in Primary Sjögren Syndrome. Acta Reumatol Port 2013;38(1):29–36.
Harboe E, Tjensvoll AB, Maroni S, Gøransson LG, Greve OJ, Beyer MK, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis 2009;68(10):1541–6.
Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum 2004;34(3):623–30.
Akasbi M, Berenguer J, Saiz A, Brito-Zerón P, Pérez-De-Lis M, Bové A, et al. White matter abnormalities in primary Sjögren syndrome. QJM 2012;105(5):433–43.
Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 1999;122 ( Pt 11):2171–82.
Saip S, Akman-Demir G, Siva A. Neuro-Behçet syndrome. Handb Clin Neurol 2014;121:1703–23.
Akman-Demir G, Bahar S, Coban O, Tasci B, Serdaroglu P. Cranial MRI in Behçet’s disease: 134 examinations of 98 patients. Neu- roradiology 2003;45(12):851–9.
Aykutlu E, Baykan B, Serdaroglu P, Gökyigit A, Akman-Demir G. Epileptic seizures in Behçet disease. Epilepsia 2002;43(8):832– 5.
Barlas NY, Akman-Demir G, Bahar SZ. Cerebral Venous Thrombosis in the Mediterranean Area in Adults. Role of Behçet’s Disease as an Underlying Cause. Mediterr J Hematol Infect Dis 2011;3(1):e2011044.
Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr 2013;13(2):62–8.
Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 2008;26(4 Suppl 50):84–90.
Akman-Demir G, Saip S, Siva A. Behçet’s Disease. Curr Treat Options Neurol 2011;13(3):290–310.
Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis--diagnosis and management. QJM 1999;92(2):103–17.
Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. J Neurol 2015;262(2):258–67.
Hoyle JC, Jablonski C, Newton HB3 Neurosarcoidosis: clinical review of a disorder with challenging inpatient presentations and diagnostic considerations. Neurohospitalist 2014;4(2):94– 101.
Hanly JG, Fisk JD, McCurdy G, Fougere L, Douglas JA. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2005;32(8):1459– 6.
Guadalupe Loya-de la Cerda D1, Avilés-Solís JC, DelgadoMontemayor MJ, Camara-Lemarroy CR, Galarza-Delgado DÁ. Isolated rheumatoid arthritis-associated cerebral vasculitis: a diagnostic challenge. Joint Bone Spine 2013;80(1):88–90.
Chang KH, Hsu YC, Chang MY, Lin CL, Wu TN, Hwang BF, et al. A Large-Scale Study Indicates Increase in the Risk of Epilepsy in Patients With Different Risk Factors, Including Rheumatoid Arthritis. Medicine (Baltimore) 2015;94(36):e1485.
Ikeda K, Takazawa T, Ito H, Ishikawa Y, Miura K, Yoshii Y, et al. Rheumatoid leptomeningitis: radiological alteration of cerebral hypoperfusion and subarachnoid lesions. Intern Med 2010;49(17):1911–6.
Kurne A, Karabudak R, Karadag O, Yalcin-Cakmakli G, Karli-Oguz K, Yavuz K, et al. An unusual central nervous system involvement in rheumatoid arthritis: combination of pachymeningitis and cerebral vasculitis. Rheumatol Int 2009;29(11):1349–53.
Gispen JG, Alarcón GS, Johnson JJ, Acton RT, Barger BO, Koopman WJ. Toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1987;14(1):74–9.
Wiik A. What you should know about PR3-ANCA. An introduction. Arthritis Res 2000;2(4):252–4.
Sierra S, Luquin N, Tardáguila M, Olivé A. Choroid plexitis as a unique neurological manifestation in granulomatosis with polyangiitis (Wegener’s disease). J Rheumatol 2014;41(6):1192– 3.
Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993;33(1):4–9.
de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001;58(8):1215–21.
Yokoyama T, Abe T, Kurakawa E, Kasuga I, Park J, Akata S, et al. A suspected case of Wegener granulomatosis accompanied with pachymeningitis and white matter lesions. [Article in Japanese] No To Shinkei 2005;57(3):221–6. [Abstract]
De Luna G, Terrier B, Kaminsky P, Le Quellec A, Maurier F, Solans R, et al. Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. Rheumatology (Oxford) 2015;54(3):424–32.
Benavente L, Morís G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol 2011;18(1):138–43.
Elsehety A, Bertorini TE. Neurologic and neuropsychiatric complications of Crohn’s disease. South Med J 1997;90(6):606–10.
Akobeng AK, Miller V, Thomas AG. Epilepsy and Crohn’s disease in children. J Pediatr Gastroenterol Nutr 1998;26(4):458–60.
Masaki T, Muto T, Shinozaki M, Kuroda T. Unusual cerebral complication associated with ulcerative colitis. J Gastroenterol 1997;32(2):251–4.
Cooke WT, Smith WT. Neurological disorders associated with adult coeliac disease. Brain 1966;89(4):683–722.
Işıkay S, Kocamaz H. Prevalence of celiac disease in children with idiopathic epilepsy in southeast Turkey. Pediatr Neurol 2014;50(5):479–81.
Dai AI, Akcali A, Varan C, Demiryürek AT. Prevalence of resistant occipital lobe epilepsy associated with celiac disease in children. Childs Nerv Syst 2014;30(6):1091–8.
Pengiran Tengah DS, Holmes GK, Wills AJ. The prevalence of epilepsy in patients with celiac disease. Epilepsia 2004;45(10):1291–3.
Chapman RW, Laidlow JM, Colin-Jones D, Eade OE, Smith CL. Increased prevalence of epilepsy in coeliac disease. Br Med J 1978;2(6132):250–1.
Lea ME, Harbord M, Sage MR. Bilateral occipital calcification associated with celiac disease, folate deficiency, and epilepsy. AJNR Am J Neuroradiol 1995;16(7):1498–500.
Fois A, Vascotto M, Di Bartolo RM, Di Marco V. Celiac disease and epilepsy in pediatric patients. Childs Nerv Syst 1994;10(7):450–4.
Ludvigsson JF, Zingone F, Tomson T, Ekbom A, Ciacci C. Increased risk of epilepsy in biopsy-verified celiac disease: a population-based cohort study. Neurology 2012;78(18):1401–7.
Canales P, Mery VP, Larrondo FJ, Bravo FL, Godoy J. Epilepsy and celiac disease: favorable outcome with a gluten-free diet in a patient refractory to antiepileptic drugs. Neurologist 2006;12(6):318–21.
Kieslich M, Errázuriz G, Posselt HG, Moeller-Hartmann W, Zanella F, Boehles H. Brain white-matter lesions in celiac disease: a prospective study of 75 diet-treated patients. Pediatrics 2001;108(2):21.
.Farré C, Humbert P, Vilar P, Varea V, Aldeguer X, Carnicer J, et al. Serological markers and HLA-DQ2 haplotype among firstdegree relatives of celiac patients. Catalonian Coeliac Disease Study Group. Dig Dis Sci 1999;44(11):2344–9.
.Diaconu G, Burlea M, Grigore I, Anton DT, Trandafir LM. Celiac disease with neurologic manifestations in children. Rev Med Chir Soc Med Nat Iasi 2013;117(1):88–94.
O’Connell MA, Harvey AS, Mackay MT, Cameron FJ. Does epilepsy occur more frequently in children with Type 1 diabetes? J Paediatr Child Health 2008;44(10):586–9.
McCorry D, Nicolson A, Smith D, Marson A, Feltbower RG, Chadwick DW. An association between type 1 diabetes and idiopathic generalized epilepsy. Ann Neurol 2006;59(1):204–6.
Mancardi MM, Striano P, Giannattasio A, Baglietto MG, Errichiello L, Zara F, et al. Type 1 diabetes and epilepsy: more than a casual association? Epilepsia 2010;51(2):320–1.
Ramakrishnan R, Appleton R. Study of prevalence of epilepsy in children with type 1 diabetes mellitus. Seizure 2012;21(4):292– 4.
Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Populationlevel evidence for an autoimmune etiology of epilepsy. JAMA Neurol 2014;71(5):569–74.
Falip M, Miró J, Carreño M, Jaraba S, Becerra JL, Cayuela N, et al. Hypoglycemic seizures and epilepsy in type I diabetes mellitus. J Neurol Sci 2014;346(1-2):307–9.
Aylward NM, Shah N, Sellers EA. The ketogenic diet for the treatment of myoclonic astatic epilepsy in a child with type 1 diabetes mellitus. Can J Diabetes 2014;38(4):223–4.
Aguirre Castaneda RL, Mack KJ, Lteif A. Successful treatment of type 1 diabetes and seizures with combined ketogenic diet and insulin. Pediatrics 2012;129(2):511–4.
.Keesey JC. Does myasthenia gravis affect the brain? J Neurol Sci 1999;170(2):77–89.
Sri-udomkajorn S, Panichai P, Liumsuwan S. Childhood myasthenia gravis: clinical features and outcomes. J Med Assoc Thai 2011;94 Suppl 3:152–7.
Matsunaga A, Yoneda M. Anti-NAE autoantibodies and clinical spectrum in Hashimoto’s encephalopathy. [Article in Japanese] Rinsho Byori 2009;57(3):271–8. [Abstract]
Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003;60(2):164–71.
Arain A, Abou-Khalil B, Moses H. Hashimoto’s encephalopathy: documentation of mesial temporal seizure origin by ictal EEG. Seizure 2001;10(6):438–41.
Vasconcellos E, Piña-Garza JE, Fakhoury T, Fenichel GM. Pediatric manifestations of Hashimoto’s encephalopathy. Pediatr Neurol 1999;20(5):394–8.
sai MH, Lee LH, Chen SD, Lu CH, Chen MT, Chuang YC. Complex partial status epilepticus as a manifestation of Hashimoto’s encephalopathy. Seizure 2007;16(8):713–6.
Mayer T, Devinsky O. Seizures, cognitive abnormalities, and abnormal magnetic resonance imaging findings in a 19-year-old woman. Rev Neurol Dis 2006;3(4):190, 195–7.
Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess CW. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996;243(8):585– 93.
Ferracci F, Moretto G, Candeago RM, Cimini N, Conte F, Gentile M, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto’s encephalopathy. Neurology 2003;60(4):712–4.
Arya R, Anand V, Chansoria M. Hashimoto encephalopathy presenting as progressive myoclonus epilepsy syndrome. Eur J Paediatr Neurol 2013;17(1):102–4.
Song TJ, Kim SJ, Kim GS, Choi YC, Kim WJ. The prevalence of thyrotoxicosis-related seizures. Thyroid 2010;20(9):955–8.
Vergely N, Garnier P, Guy C, Khalfallah Y, Estour B. Seizure during Graves’ disease. Epileptic Disord 2009;11(2):136–7

APA	KÜRTÜNCÜ M, ALTUNRENDE B, AKMAN-DEMİR G (2016). Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. , 53 - 66. 10.5505/epilepsi.2015.15807
Chicago	KÜRTÜNCÜ Murat,ALTUNRENDE Burcu,AKMAN-DEMİR Gülşen Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. (2016): 53 - 66. 10.5505/epilepsi.2015.15807
MLA	KÜRTÜNCÜ Murat,ALTUNRENDE Burcu,AKMAN-DEMİR Gülşen Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. , 2016, ss.53 - 66. 10.5505/epilepsi.2015.15807
AMA	KÜRTÜNCÜ M,ALTUNRENDE B,AKMAN-DEMİR G Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. . 2016; 53 - 66. 10.5505/epilepsi.2015.15807
Vancouver	KÜRTÜNCÜ M,ALTUNRENDE B,AKMAN-DEMİR G Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. . 2016; 53 - 66. 10.5505/epilepsi.2015.15807
IEEE	KÜRTÜNCÜ M,ALTUNRENDE B,AKMAN-DEMİR G "Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar." , ss.53 - 66, 2016. 10.5505/epilepsi.2015.15807
ISNAD	KÜRTÜNCÜ, Murat vd. "Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar". (2016), 53-66. https://doi.org/10.5505/epilepsi.2015.15807

APA	KÜRTÜNCÜ M, ALTUNRENDE B, AKMAN-DEMİR G (2016). Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. Epilepsi, 22(Suppl. 1), 53 - 66. 10.5505/epilepsi.2015.15807
Chicago	KÜRTÜNCÜ Murat,ALTUNRENDE Burcu,AKMAN-DEMİR Gülşen Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. Epilepsi 22, no.Suppl. 1 (2016): 53 - 66. 10.5505/epilepsi.2015.15807
MLA	KÜRTÜNCÜ Murat,ALTUNRENDE Burcu,AKMAN-DEMİR Gülşen Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. Epilepsi, vol.22, no.Suppl. 1, 2016, ss.53 - 66. 10.5505/epilepsi.2015.15807
AMA	KÜRTÜNCÜ M,ALTUNRENDE B,AKMAN-DEMİR G Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. Epilepsi. 2016; 22(Suppl. 1): 53 - 66. 10.5505/epilepsi.2015.15807
Vancouver	KÜRTÜNCÜ M,ALTUNRENDE B,AKMAN-DEMİR G Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar. Epilepsi. 2016; 22(Suppl. 1): 53 - 66. 10.5505/epilepsi.2015.15807
IEEE	KÜRTÜNCÜ M,ALTUNRENDE B,AKMAN-DEMİR G "Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar." Epilepsi, 22, ss.53 - 66, 2016. 10.5505/epilepsi.2015.15807
ISNAD	KÜRTÜNCÜ, Murat vd. "Epilepsi İle İlişkili Sistemik Otoimmün Hastalıklar". Epilepsi 22/Suppl. 1 (2016), 53-66. https://doi.org/10.5505/epilepsi.2015.15807